Advertisement
Canada markets close in 2 hours 25 minutes

  • S&P/TSX

    21,853.30
    -20.42 (-0.09%)
     

  • S&P 500

    5,036.98
    -34.65 (-0.68%)
     

  • DOW

    38,054.36
    -406.56 (-1.06%)
     

  • CAD/USD

    0.7315
    +0.0017 (+0.23%)
     

  • CRUDE OIL

    82.79
    -0.02 (-0.02%)
     

  • Bitcoin CAD

    88,177.30
    -800.35 (-0.90%)
     

  • CMC Crypto 200

    1,392.47
    +9.90 (+0.72%)
     

  • GOLD FUTURES

    2,341.50
    +3.10 (+0.13%)
     

  • RUSSELL 2000

    1,972.71
    -22.71 (-1.14%)
     

  • 10-Yr Bond

    4.7040
    +0.0520 (+1.12%)
     

  • NASDAQ

    15,558.87
    -153.88 (-0.98%)
     

  • VOLATILITY

    16.42
    +0.45 (+2.82%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6810
    -0.0009 (-0.13%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, DOWNBEAT GDP

Caterpillar sinks 7% after earnings, management sees weakness in Europe, Asia-Pacific

Bellerophon Presents Positive Interim Data on INOpulse

Zacks Equity Research
Updated

Bellerophon Therapeutics, Inc. BLPH announced positive interim data from part 2 of a phase II study on INOpulse for the treatment of pulmonary arterial hypertension (PAH).  Results from the study supported data from part 1 of the phase II study on INOpulse and also indicated a sustainability of benefit in PAH patients.

The company also announced that the FDA has issued a Special Protocol Assessment for the phase III program on INOpulse, which is expected to be initiated later this year. The phase III program will include two studies – one with two treatment arms (iNO 75 and placebo) and the other with three treatment arms (iNO 75, iNO 50 and placebo) – undertaken either sequentially or simultaneously.

We note that INOpulse is also being evaluated for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is currently in phase II development.

According to information provided by the company, there are about 15,000 and 20,000 patients diagnosed with PAH in the U.S. and Europe, respectively.

The PAH treatment market is highly crowded with drugs like Orenitram, Remodulin, Tracleer, Adcirca and others.

Meanwhile, the company plans to carry out further studies on INOpulse for the treatment of PH-COPD and idiopathic pulmonary fibrosis during 2016.

Bellerophon carries a Zacks Rank #2 (Buy). Gilead Sciences Inc. GILD, Medivation, Inc. MDVN and Regeneron Pharmaceuticals, Inc. REGN, are some other favorably ranked stocks in the health care sector, each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
REGENERON PHARM (REGN): Free Stock Analysis Report
 
GILEAD SCIENCES (GILD): Free Stock Analysis Report
 
MEDIVATION INC (MDVN): Free Stock Analysis Report
 
BELLEROPHON THR (BLPH): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research